Development and validation of a nomogram for assessing hepatocellular carcinoma risk after SVR in hepatitis C patients with advanced fibrosis and cirrhosis

Table 3 HCC incidence according to HCC risk score of derivation cohort

	Number of patients (N)	Incidence per-year (%)	3-Year cumulative incidence (%)	5-Year cumulative incidence (%)	7-Year cumulative incidence (%)
Derivation cohort
Low-risk group	96	0.18	0.00	0.00	1.04
Intermediate-risk group	192	1.29	1.56	5.73	7.29
High-risk group	97	4.45	9.28	18.56	22.68
Internal validation cohort
Low-risk group	45	0.39	0.00	2.22	2.22
Intermediate-risk group	78	1.60	5.13	7.69	8.97
High-risk group	43	3.80	6.98	18.60	18.60
External validation cohort
Low-risk group	61	0.00	0.00	0.00	–
Intermediate-risk group	81	3.65	6.17	8.64	–
High-risk group	69	9.02	13.04	18.84	–

Low-risk group, HCC risk score < 95.45points; Intermediate-risk group, HCC risk score 95.45–124.76 points; High-risk group, HCC risk score > 124.76 points

ISSN: 1750-9378